Cancel
Karen Chagin, M.D.
SVP Early-Stage Development
@
Adaptimmune
About Karen Chagin, M.D.
Karen Chagin, M.D., is the SVP of Early-Stage Development with a robust background in pediatric hematology and oncology, and extensive experience in pharmaceutical development.
Known information
Karen Chagin, M.D., currently serves as the Senior Vice President of Early-Stage Development. She holds a Bachelor of Arts from the University of Pennsylvania and earned her Medical Degree from Temple University School of Medicine. Dr. Chagin completed her residency at Children’s Memorial Hospital in Chicago, followed by a fellowship in pediatric hematology and oncology at The Children’s Hospital of Philadelphia. Her career in the pharmaceutical industry began in 2009 at GSK, where she was a Safety Development leader and Medical Director for Promacta/Revolade. She has previously held significant roles including Chief Medical Officer at Tmunity and Head of Kite Philadelphia after Kite’s acquisition of Tmunity. Additionally, she served as a Scientific Director in Oncology Early Development at Janssen. Throughout her career, Dr. Chagin has led and contributed to the registration of several products and indications globally, demonstrating her leadership and expertise in the field.
About Adaptimmune
Adaptimmune is a biotechnology company specializing in the development of T-cell-based therapies for cancer treatment, with a focus on engineering patients' own cells to combat solid tumors.
Report inaccurate information
